Johnson & Johnson Innovation recently launched over a dozen new collaborations to impact health care, marking more than 350 partnerships since the company's establishment in 2012.
The new collaborations involve Alzheimer's disease and gene therapy, exploring microbiome in sleep, predicting neurodegenerative diseases, intercepting and curing lung cancer, developing a saliva test for cancer, harnessing bacteria to fight skin disease and therapeutics for obesity, a Johnson & Johnson release said.
The collaborations with various companies and institutes are part of the Johnson & Johnson Innovation's goal to address areas of high medical need, the release said.
“Our highest priority is to improve the health of people around the globe, and each collaboration announced today represents a unique opportunity to explore novel therapeutics, medical devices and consumer health solutions,” Johnson & Johnson Executive Vice President and Chief Scientific Officer Paul Stoffels said in the release. “By advancing transformative health care innovations together with entrepreneurs, academic centers and institutions, we are one step closer to addressing many pressing global healthcare challenges.”
“At Johnson & Johnson Innovation, we have a collaborative approach to partnering and tailor each deal to the needs of the company and its technology so we can accelerate the best science to solve today’s healthcare challenges,” Johnson & Johnson Innovation global head Robert Urban said in the release.
